CompanyHCWBNasdaqMiramar, FL

HCW Biologics

HCW Biologics develops fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia.

SEC EDGAR ClinicalTrials.gov hcwbiologics.com

DEF 14AOct 1Latest SEC filing

Sep 24Latest story

September 2026

HCW Biologics prices $1.5 million private placement with existing investor

Sep 24FinancingHCW Biologics

HCW Biologics signs exclusive distribution deal with Akron Biotech for HCW11-006

Sep 8PartnershipHCW Biologics

August 2026

HCW Biologics S-1 flags new Nasdaq market-value rule and SEC stay on its approval

Aug 20FinancingHCW Biologics

HCW Biologics reports Q2 2026 results, alopecia data and going concern doubt

Aug 14Quarterly updateHCW Biologics

HCW Biologics reports $1.6 million private securities sale in SEC filing

Aug 6FinancingHCW Biologics

July 2026

HCW Biologics prices $1.6 million private placement offering

Jul 29FinancingHCW Biologics